Brigatinib vs Ceritinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline

Brigatinib

Marketed by Takeda Pharmaceutical Company

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02737501 · Phase 3 · completed

This was a randomized, open-label active-controlled trial of 275 participants, with progression-free survival assessed by a blinded independent review committee as the primary clinical endpoint. The primary comparison favored brigatinib and was statistically significant, but the lack of participant and investigator blinding limits the strength of the evidence.

Next expected readout: November 2026 · NCT04223596 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months (missed)

Result source: NCT03596866

Ceritinib

Marketed by Novartis

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT01828099 · Phase 3 · completed

The trial was randomized and actively controlled, with 189 patients assigned to ceritinib and 187 to chemotherapy, but treatment was open-label rather than double-blind. Its clinical primary endpoint, progression-free survival assessed by an independent review committee, was met: median progression-free survival was 16.6 versus 8.1 months, with hazard ratio 0.55 (95% CI 0.42–0.73; p<0.001).

Next expected readout: December 2026 · NCT02321501 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1) (met)

Result source: NCT01828099

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBrigatinibCeritinib
PFS, median24.0 vs 11.1vs Crizotinib90 mg QD/180 QD · n 137NCT02737501
10 other results
  • 19.3 vs 19.2 n 125 · Phase 3 · primary NCT03596866
  • 16.8 vs 16.6 n 125 · Phase 3 · secondary NCT03596866
  • 9.2 90 mg · n 112 · Phase 2 · secondary NCT02094573
  • 15.6 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 12.6 90 mg QD · n 15 · Phase 1/2 · secondary NCT01449461
  • 11 90 mg QD-180 mg QD · n 21 · Phase 1/2 · secondary NCT01449461
  • 5.4 180 mg QD/90 mg BID · n 40 · Phase 1/2 · secondary NCT01449461
  • 5.4 240 mg QD/120 mg BID/300 mg QD · n 7 · Phase 1/2 · secondary NCT01449461
  • 5.4 120 mg QD/60 mg BID · n 17 · Phase 1/2 · secondary NCT01449461
  • 1.8 30 mg QD/60 mg QD · n 5 · Phase 1/2 · secondary NCT01449461
16.6 vs 8.1vs Chemotherapyn 189NCT01828099
10 other results
OS, median25.9b90 mg · n 112NCT02094573
8 other results
  • 40.6 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 21.3 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · secondary NCT03535740
  • 11.6 90 mg QD · n 11 · Phase 1/2 · secondary NCT01449461
  • 17.9 90 mg QD-180 mg QD · n 17 · Phase 1/2 · secondary NCT01449461
  • 8.3 240 mg QD/120 mg BID/300 mg QD · n 11 · Phase 1/2 · secondary NCT01449461
  • 7.3 180 mg QD/90 mg BID · n 25 · Phase 1/2 · secondary NCT01449461
  • 7.3 120 mg QD/60 mg BID · n 12 · Phase 1/2 · secondary NCT01449461
  • 5.3 30 mg QD/60 mg QD · n 6 · Phase 1/2 · secondary NCT01449461
62.9 vs 40.7vs Chemotherapyn 189NCT01828099
5 other results
ORR74.5% vs 62.3%vs Crizotinib90 mg QD/180 QD · n 137NCT02737501
6 other results
  • 45.5% 90 mg · n 112 · Phase 2 · primary NCT02094573
  • 57.3% 90 mg - 180 mg · n 110 · Phase 2 · primary NCT02094573
  • 26.2% 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · primary NCT03535740
  • 51.8% 90 mg · n 112 · Phase 2 · secondary NCT02094573
  • 56.4% 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 26.2% 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · secondary NCT03535740
72.5% vs 26.7%vs Chemotherapyn 189NCT01828099
12 other results
Duration of response, median33.1 vs 13.8vs Crizotinib90 mg QD/180 QD · n 102NCT02737501
2 other results
  • 12 90 mg · n 51 · Phase 2 · secondary NCT02094573
  • 13.8 90 mg - 180 mg · n 63 · Phase 2 · secondary NCT02094573
23.9 vs 11.1vs Chemotherapyn 137NCT01828099
12 other results

PFS, median

Brigatinib
24.0 vs 11.1vs Crizotinib90 mg QD/180 QD · n 137NCT02737501
10 other results
  • 19.3 vs 19.2 n 125 · Phase 3 · primary NCT03596866
  • 16.8 vs 16.6 n 125 · Phase 3 · secondary NCT03596866
  • 9.2 90 mg · n 112 · Phase 2 · secondary NCT02094573
  • 15.6 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 12.6 90 mg QD · n 15 · Phase 1/2 · secondary NCT01449461
  • 11 90 mg QD-180 mg QD · n 21 · Phase 1/2 · secondary NCT01449461
  • 5.4 180 mg QD/90 mg BID · n 40 · Phase 1/2 · secondary NCT01449461
  • 5.4 240 mg QD/120 mg BID/300 mg QD · n 7 · Phase 1/2 · secondary NCT01449461
  • 5.4 120 mg QD/60 mg BID · n 17 · Phase 1/2 · secondary NCT01449461
  • 1.8 30 mg QD/60 mg QD · n 5 · Phase 1/2 · secondary NCT01449461
Ceritinib
16.6 vs 8.1vs Chemotherapyn 189NCT01828099
10 other results

OS, median

Brigatinib
25.9b90 mg · n 112NCT02094573
8 other results
  • 40.6 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 21.3 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · secondary NCT03535740
  • 11.6 90 mg QD · n 11 · Phase 1/2 · secondary NCT01449461
  • 17.9 90 mg QD-180 mg QD · n 17 · Phase 1/2 · secondary NCT01449461
  • 8.3 240 mg QD/120 mg BID/300 mg QD · n 11 · Phase 1/2 · secondary NCT01449461
  • 7.3 180 mg QD/90 mg BID · n 25 · Phase 1/2 · secondary NCT01449461
  • 7.3 120 mg QD/60 mg BID · n 12 · Phase 1/2 · secondary NCT01449461
  • 5.3 30 mg QD/60 mg QD · n 6 · Phase 1/2 · secondary NCT01449461
Ceritinib
62.9 vs 40.7vs Chemotherapyn 189NCT01828099
5 other results

ORR

Brigatinib
74.5% vs 62.3%vs Crizotinib90 mg QD/180 QD · n 137NCT02737501
6 other results
  • 45.5% 90 mg · n 112 · Phase 2 · primary NCT02094573
  • 57.3% 90 mg - 180 mg · n 110 · Phase 2 · primary NCT02094573
  • 26.2% 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · primary NCT03535740
  • 51.8% 90 mg · n 112 · Phase 2 · secondary NCT02094573
  • 56.4% 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 26.2% 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · secondary NCT03535740
Ceritinib
72.5% vs 26.7%vs Chemotherapyn 189NCT01828099
12 other results

Duration of response, median

Brigatinib
33.1 vs 13.8vs Crizotinib90 mg QD/180 QD · n 102NCT02737501
2 other results
  • 12 90 mg · n 51 · Phase 2 · secondary NCT02094573
  • 13.8 90 mg - 180 mg · n 63 · Phase 2 · secondary NCT02094573
Ceritinib
23.9 vs 11.1vs Chemotherapyn 137NCT01828099
12 other results
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety

Coverage. Brigatinib: 14 of 14 rows · Ceritinib: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBrigatinib
Rows use multiple source trials
Ceritinib
Rows use multiple source trials
Disease Control
responder rate · % of participants
85.4% (n=137) vs 86.2% (n=138) Crizotinib90 mg QD/180 QDa,b
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
84.7% (n=189) vs 73.8% (n=187) Chemotherapyc,a,b
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more dose
89.4% (n=189) vs 75.9% (n=187) Chemotherapy
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Disease Control
responder rate · % of participants
No placebo or comparator arm
81.3% (n=112)90 mgc,a,d,b
NCT02094573 · Phase 2
show 1 more dose
86.4% (n=110)90 mg - 180 mg
NCT02094573 · Phase 2
70% (n=20)a,d,b
NCT02450903 · Phase 2 · registry result, not featured evidence
2 other source trials
77.7% (n=103)
NCT02040870 · Phase 1/2 · registry result, not featured evidence
67% (n=103)
NCT02040870 · Phase 1/2 · registry result, not featured evidence
Duration of Response
time to event · months
No placebo or comparator arm
12 months90 mgc,e,a,d,b
NCT02094573 · Phase 2
show 1 more dose
13.8 months90 mg - 180 mg
NCT02094573 · Phase 2
14.19 monthsc,e,a,d,b
NCT01283516 · Phase 1
show 1 more dose
21.75 months
NCT01283516 · Phase 1
Intracranial Duration of Response
time to event · months
17.413 vs NA Alectinib monthsf,b
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
16.6 vs NA Chemotherapy monthsf,b
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Intracranial ORR
responder rate · % of participants
No placebo or comparator arm
14.5% (n=55)90 mg/180 mg With Optional Dose Escalation to 240 mgg,d,b
NCT03535740 · Phase 2 · registry result, not featured evidence
0% (n=2)g,d,b
NCT02450903 · Phase 2 · registry result, not featured evidence
6 other source trials
20% (n=10)
NCT01685138 · Phase 2 · registry result, not featured evidence
61.5% (n=13)
NCT01685138 · Phase 2 · registry result, not featured evidence
45% (n=20) @ 24wk750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
35.7% (n=28) @ 24wk750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
39.1% (n=23)
NCT02040870 · Phase 1/2 · registry result, not featured evidence
0% (n=9)
NCT02040870 · Phase 1/2 · registry result, not featured evidence
ORR
responder rate · % of participants
No placebo or comparator arm
45.5% (n=112)90 mgc,e,a,d,b
NCT02094573 · Phase 2
show 3 more doses
51.8% (n=112)90 mg
NCT02094573 · Phase 2
57.3% (n=110)90 mg - 180 mg
NCT02094573 · Phase 2
56.4% (n=110)90 mg - 180 mg
NCT02094573 · Phase 2
73.5% (n=83)c,e,a,d,b
NCT01283516 · Phase 1
show 1 more dose
65.1% (n=83)
NCT01283516 · Phase 1
Overall Survival
time to event · months
No placebo or comparator arm
25.9 months90 mgc,a,d,b
NCT02094573 · Phase 2
show 1 more dose
40.6 months90 mg - 180 mg
NCT02094573 · Phase 2
17.3 monthsa,d,b
NCT02450903 · Phase 2 · registry result, not featured evidence
3 other source trials
51.3 months
NCT01685138 · Phase 2 · registry result, not featured evidence
15.6 months @ 24wk750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
17.5 months
NCT02040870 · Phase 1/2 · registry result, not featured evidence
PFS
time to event · months
No placebo or comparator arm
9.2 months90 mgc,e,a,d,b
NCT02094573 · Phase 2
show 1 more dose
15.6 months90 mg - 180 mg
NCT02094573 · Phase 2
15.21 monthsc,e,a,d,b
NCT01283516 · Phase 1
show 1 more dose
19.32 months
NCT01283516 · Phase 1
Time to Response
time to event · months
1.84 vs 1.873 Crizotinib months90 mg QD/180 QDa,b
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
1.42 vs 3.08 Chemotherapy months*c,a,b
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to months from 6.14 weeks as posted
show 1 more dose
1.45 vs 2.93 Chemotherapy months*
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to months from 6.29 weeks as posted
Time to Response
time to event · months
No placebo or comparator arm
1.8 months90 mgc,a,d,b
NCT02094573 · Phase 2
show 1 more dose
1.9 months90 mg - 180 mg
NCT02094573 · Phase 2
1.8 monthsa,d,b
NCT02450903 · Phase 2 · registry result, not featured evidence
6 other source trials
2.5 months
NCT01685138 · Phase 2 · registry result, not featured evidence
2.2 months
NCT01685138 · Phase 2 · registry result, not featured evidence
3 months @ 24wk750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
2.2 months @ 24wk750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
1.9 months
NCT02040870 · Phase 1/2 · registry result, not featured evidence
1.8 months
NCT02040870 · Phase 1/2 · registry result, not featured evidence
Dropout rate
85.4%90 mg QD/180 QDh
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 12 more results
97.6%
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone90 mg
NCT02094573 · Phase 2
n/a: no completion milestone90 mg - 180 mg
NCT02094573 · Phase 2
—90/180 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
—240 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone90 mg/180 mg
NCT03410108 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone90 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone90 mg QD-180 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone240 mg QD/120 mg BID/300 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone180 mg QD/90 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone120 mg QD/60 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone30 mg QD/60 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestonei
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 17 more results
n/a: no completion milestoneCeritinib
NCT01828112 · Phase 3 · monotherapy
—Ceritinib (On-treatment)
NCT01828112 · Phase 3
n/a: no completion milestone750 mg
NCT01283516 · Phase 1
n/a: no completion milestone700 mg
NCT01283516 · Phase 1
n/a: no completion milestone600 mg
NCT01283516 · Phase 1
n/a: no completion milestone500 mg
NCT01283516 · Phase 1
n/a: no completion milestone400 mg
NCT01283516 · Phase 1
n/a: no completion milestone300 mg
NCT01283516 · Phase 1
n/a: no completion milestone200 mg
NCT01283516 · Phase 1
n/a: no completion milestone100 mg
NCT01283516 · Phase 1
n/a: no completion milestone50 mg
NCT01283516 · Phase 1
n/a: no completion milestone
NCT02450903 · Phase 2 · registry result, not featured evidence
74.2%LDK378 (Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
—LDK378 Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
—750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT02040870 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—90 mg QD/180 QDh
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 12 more results
—
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3.6%90 mg
NCT02094573 · Phase 2
12.7%90 mg - 180 mg
NCT02094573 · Phase 2
—90/180 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
—240 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
3.8%90 mg/180 mg
NCT03410108 · Phase 2 · registry result, not featured evidence
16.7%90 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
9.4%90 mg QD-180 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
26.7%240 mg QD/120 mg BID/300 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
8.3%180 mg QD/90 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
11.1%120 mg QD/60 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
0%30 mg QD/60 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
12.7%i
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 17 more results
6.1%Ceritinib
NCT01828112 · Phase 3 · monotherapy
—Ceritinib (On-treatment)
NCT01828112 · Phase 3
11%750 mg
NCT01283516 · Phase 1
0%700 mg
NCT01283516 · Phase 1
20%600 mg
NCT01283516 · Phase 1
0%500 mg
NCT01283516 · Phase 1
0%400 mg
NCT01283516 · Phase 1
0%300 mg
NCT01283516 · Phase 1
0%200 mg
NCT01283516 · Phase 1
0%100 mg
NCT01283516 · Phase 1
0%50 mg
NCT01283516 · Phase 1
15%
NCT02450903 · Phase 2 · registry result, not featured evidence
14.5%LDK378 (Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
—LDK378 Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
—750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
8.6%750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
6.8%
NCT02040870 · Phase 1/2 · registry result, not featured evidence
Serious AEs
41.2%90 mg QD/180 QDh
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 12 more results
30.4%
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
53.2%90 mg
NCT02094573 · Phase 2
62.7%90 mg - 180 mg
NCT02094573 · Phase 2
46.6%90/180 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
23.1%240 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
35.6%90 mg/180 mg
NCT03410108 · Phase 2 · registry result, not featured evidence
55.6%90 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
43.8%90 mg QD-180 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
73.3%240 mg QD/120 mg BID/300 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
62.5%180 mg QD/90 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
55.6%120 mg QD/60 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
16.7%30 mg QD/60 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
49.2%i
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 17 more results
—Ceritinib
NCT01828112 · Phase 3 · monotherapy
49.6%Ceritinib (On-treatment)
NCT01828112 · Phase 3
56.9%750 mg
NCT01283516 · Phase 1
60%700 mg
NCT01283516 · Phase 1
70%600 mg
NCT01283516 · Phase 1
40%500 mg
NCT01283516 · Phase 1
50%400 mg
NCT01283516 · Phase 1
33.3%300 mg
NCT01283516 · Phase 1
33.3%200 mg
NCT01283516 · Phase 1
50%100 mg
NCT01283516 · Phase 1
0%50 mg
NCT01283516 · Phase 1
45%
NCT02450903 · Phase 2 · registry result, not featured evidence
—LDK378 (Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
40.3%LDK378 Ceritinib)
NCT01685138 · Phase 2 · registry result, not featured evidence
47.9%750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
—750 mg
NCT01685060 · Phase 2 · registry result, not featured evidence
35%
NCT02040870 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
90 mg QD/180 QDh
diarrhoea 57.4%
blood creatine phosphokinase increased 50%
cough 36%
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 12 more results
blood creatine phosphokinase increased 73.6%
aspartate aminotransferase increased 56.8%
alanine aminotransferase increased 47.2%
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
90 mg
nausea 43.1%
vomiting 40.4%
headache 35.8%
NCT02094573 · Phase 2
90 mg - 180 mg
nausea 50%
diarrhoea 46.4%
cough 40.9%
NCT02094573 · Phase 2
90/180 mg
diarrhoea 39.8%
blood creatine phosphokinase increased 34%
nausea 28.2%
NCT03535740 · Phase 2 · registry result, not featured evidence
240 mg
diarrhoea 53.8%
blood creatine phosphokinase increased 38.5%
aspartate aminotransferase increased 23.1%
NCT03535740 · Phase 2 · registry result, not featured evidence
90 mg/180 mg
blood creatine phosphokinase increased 77.9%
hypertension 47.1%
diarrhoea 45.2%
NCT03410108 · Phase 2 · registry result, not featured evidence
90 mg QD
fatigue 50%
diarrhoea 44.4%
headache 44.4%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
90 mg QD-180 mg QD
diarrhoea 53.1%
fatigue 50%
nausea 50%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
240 mg QD/120 mg BID/300 mg QD
fatigue 80%
cough 53.3%
diarrhoea 53.3%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
180 mg QD/90 mg BID
nausea 68.8%
diarrhoea 43.8%
fatigue 39.6%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
120 mg QD/60 mg BID
fatigue 50%
nausea 50%
aspartate aminotransferase increased 38.9%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
30 mg QD/60 mg QD
abdominal pain 50%
nausea 50%
electrocardiogram qt prolonged 33.3%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
i
diarrhoea 84.7%
nausea 68.8%
vomiting 67.2%
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 14 more results
diarrhoea 73%
nausea 63.5%
vomiting 53%
NCT01828112 · Phase 3
750 mg
diarrhoea 86.7%
nausea 84.3%
vomiting 62.4%
NCT01283516 · Phase 1
700 mg
nausea 100%
alanine aminotransferase increased 80%
diarrhoea 80%
NCT01283516 · Phase 1
600 mg
nausea 100%
diarrhoea 80%
fatigue 80%
NCT01283516 · Phase 1
500 mg
nausea 90%
diarrhoea 70%
dyspnoea 50%
NCT01283516 · Phase 1
400 mg
nausea 71.4%
diarrhoea 64.3%
vomiting 57.1%
NCT01283516 · Phase 1
300 mg
nausea 66.7%
abdominal pain 33.3%
anaemia 33.3%
NCT01283516 · Phase 1
200 mg
vomiting 100%
cough 66.7%
diarrhoea 66.7%
NCT01283516 · Phase 1
100 mg
asthenia 50%
axillary pain 50%
blood lactate dehydrogenase increased 50%
NCT01283516 · Phase 1
50 mg
dyspnoea 100%
blood lactate dehydrogenase increased 50%
bronchitis 50%
NCT01283516 · Phase 1
diarrhoea 85%
nausea 80%
vomiting 65%
NCT02450903 · Phase 2 · registry result, not featured evidence
diarrhoea 85.5%
nausea 78.2%
vomiting 71.8%
NCT01685138 · Phase 2 · registry result, not featured evidence
750 mg
diarrhoea 82.1%
nausea 82.1%
vomiting 65.7%
NCT01685060 · Phase 2 · registry result, not featured evidence
diarrhoea 74.8%
vomiting 61.2%
alanine aminotransferase increased 59.2%
NCT02040870 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation context differs: registered conditions differ.
  2. bThe assessment timepoint is not available for both results.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dTreatment context has not been resolved for both arms.
  5. eTrial phases differ: Phase 1 versus Phase 2.
  6. fPopulation context differs: prior_therapy differs (naive versus experienced).
  7. gPopulation comparability has not been reviewed for both studies.
  8. hPopulation comparability has not been reviewed for 11 of these studies.
  9. iPopulation comparability has not been reviewed for 17 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Brigatinib

Intracranial ORR 66% (n=47) vs 14.3% (n=49) Crizotinib90 mg QD/180 QD
responder rate · % of participants
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 1 more result
73.3% (n=30) vs 67.7% (n=31) Alectinib
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Intracranial PFS 23.951 vs 5.52 Crizotinib months90 mg QD/180 QD
absolute value · months
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
EORTC QLQ-C30 GHS 4.007 vs -4.088 Crizotinib score @ 144wk90 mg QD/180 QD
absolute change · score
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
ORR 52% (n=125) vs 61% (n=123) Alectinib
responder rate · % of participants
BIRC Assessed
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Duration of Response 17.544 vs 20.205 Alectinib months
time to event · months
BIRC Assessed
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Response 1.873 vs 1.84 Alectinib months
time to event · months
BIRC Assessed
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Cumulative Incidence Intracranial Progression 0.115 vs 0.076 Alectinib probability @ 26wk
absolute value · probability
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 3 more results
0.218 vs 0.171 Alectinib probability @ 52wk
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.305 vs 0.209 Alectinib probability @ 78wk
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
0.388 vs 0.248 Alectinib probability @ 104wk
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
CNS ORR 47.4% (n=19)90 mg
responder rate · % of participants
No placebo or comparator arm
NCT02094573 · Phase 2
show 3 more results
73.3% (n=15)90 mg - 180 mg
NCT02094573 · Phase 2
12.1% (n=33)90 mg
NCT02094573 · Phase 2
16.7% (n=36)90 mg - 180 mg
NCT02094573 · Phase 2
Intracranial PFS 12.8 months90 mg
absolute value · months
No placebo or comparator arm
NCT02094573 · Phase 2
show 7 more results
12.8 months90 mg - 180 mg
NCT02094573 · Phase 2
5.224 months90 mg/180 mg With Optional Dose Escalation to 240 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
36.8 months90 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
NA months90 mg QD-180 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
7.3 months240 mg QD/120 mg BID/300 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
14.4 months180 mg QD/90 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
6.7 months120 mg QD/60 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
Duration of Response 6.341 months90 mg/180 mg With Optional Dose Escalation to 240 mg
time to event · months
No placebo or comparator arm
IRC-Assessed DOR
NCT03535740 · Phase 2 · registry result, not featured evidence
PFS 3.811 months90 mg/180 mg With Optional Dose Escalation to 240 mg
time to event · months
No placebo or comparator arm
IRC-Assessed PFS
NCT03535740 · Phase 2 · registry result, not featured evidence
Disease Control 54.4% (n=103)90 mg/180 mg With Optional Dose Escalation to 240 mg
responder rate · % of participants
No placebo or comparator arm
IRC-Assessed DCR
NCT03535740 · Phase 2 · registry result, not featured evidence

+ 6 further endpoints in the CSV export.

Ceritinib

Intracranial 72.7% (n=22) vs 27.3% (n=22) Chemotherapy
responder rate · % of participants
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Intracranial Disease Control 86.4% (n=22) vs 90.9% (n=22) Chemotherapy
responder rate · % of participants
NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Disease Control 76.4% (n=140) @ 24wk750 mg
responder rate · % of participants
No placebo or comparator arm
DCR per Investigator
NCT01685060 · Phase 2 · registry result, not featured evidence
show 1 more result
90.3% (n=124)
DCR per Investigator
NCT01685138 · Phase 2 · registry result, not featured evidence
PFS 16.6 months
time to event · months
No placebo or comparator arm
PFS per Investigator
NCT01685138 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brigatinib's landscape · Ceritinib's landscape